Study of Gemcitabine and Carboplatin in the Treatment of Metastatic or Recurrent Cholangiocarcinoma/Gallbladder Cancer

1. Patients must have biopsy-proven locally-advanced, metastatic or recurrent adenocarcinoma of the biliary ducts or gallbladder.
2. Patients must have measurable disease.
3. Patients must be 18 years or older.
4. Patients must have a NCI CTC Performance Status of 0-2.
5. Patients must have a life expectancy of \>= 3 months.
6. Patients must not have any prior chemotherapy for metastatic disease. Prior adjuvant radiation therapy and chemotherapy with 5FU and/or gemcitabine is allowed.
7. At least 3 weeks should have elapsed since any surgery requiring general anesthesia.
8. Patients must have no prior malignancies except for basal or squamous skin cancers, cervical carcinoma-in-situ.
9. Pregnant patients are not eligible. Non-pregnant status will be determined in all women of childbearing potential. All patients will be required to use an effective means of contraception if sexually active during therapy.
10. Initial Required Laboratory Values:

    * 1\. Absolute neutrophil count \>= 1,500/mm3, platelet count \>= 100,000/mm3, and hemoglobin \>= 9 g/dL.
    * 2\. Serum creatinine should be \<= 2 mg/dL.
    * 3\. Serum bilirubin should be \<= 3.0 mg/dL (biliary stents allowed).
    * 4\. Serum transaminases should be \<= 5-fold the institutional upper limits.
11. Patients must not have any co-existing severe medical illnesses, such as unstable angina, uncontrolled diabetes mellitus, uncontrolled arrhythmia or uncontrolled infection.
12. Patients must be able to sign an informed consent.